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PlateletsIntroduction: The high shear rates induced by left ventricular assist devices cause acquired von Willebrand dis-
ease (aVWD). We hypothesised that an ex vivo model could be established to study whether mechanical shear
stress alone causes aVWD or whether this process depends also on the VWF cleavage protein ADAMTS-13 and
on platelets.
Materials and methods: Healthy volunteers and two patients with congenital ADAMTS-13 deﬁciency donated
blood. In vitro closed extracorporeal circuits were established usingmedically approved left ventricular assist de-
vices (LVAD). VWF multimers were quantiﬁed by gel electrophoresis; VWF antigen, ristocetin cofactor activity
(VWF:RCo), ADAMTS-13 levels and platelet function were assessed.
Results: The high shear stress in the extracorporeal circulation rapidly decreased VWF:RCo and thereby the
VWF:RCo/VWF:Ag ratio by 47% (p b 0.01) to pathologically low values. Concomitantly, high molecular weight
multimers (HMWM) decreased: up to 14–15 mers were visible on the gels at baseline, which were reduced by
a maximum of 6–7 mers, corresponding to an average 68% lower densitometry signal of HMWM (p b 0.001).
This was accompanied by marked reduction of aggregation by various agonists (p b 0.005). In contrast, the
two patientswith congenital thrombocytopenic purpurawith virtually complete deﬁciency of ADAMTS-13 activ-
ity had only a minimal or no decrease inmultimers (p b 0.005 vs. healthy controls). Similarly, no or minimal de-
pletion of large multimers occurred, when normal plasma circulated without platelets.
Conclusion:An in vitromodel for LVAD associated aVWDdemonstrated that ADAMTS-13 and platelets contribute
to the depletion of HMWM of VWF.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
von Willebrand factor (VWF) is a high molecular weight glycopro-
tein that mediates platelet adhesion at the site of vascular injury, espe-
cially under high ﬂuid shear conditions [1]. VWF is secreted from
endothelial cells as ultra-large multimers which are processed into
smaller regular sized multimers through enzymatic cleavage by thee; VWF, von Willebrand factor;
rand factor antigen; VWF:RCo,
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. This is an open access article undermetalloprotease ADAMTS 13 thereafter [2]. The larger VWF multimers
are the most haemostatically competent [3], and the loss of these is as-
sociatedwith the severe bleeding complications as seen in patientswith
type 2A von Willebrand disease (VWD). Apart from congenital VWD,
acquired type 2A VWD may arise in patients with aortic stenosis [4–7]
or patients with left ventricular assist devices [8]. On the other hand,
loss of VWFmultimer size regulation caused by severe ADAMTS-13 de-
ﬁciency (as observed in patients with thrombotic thrombocytopenic
purpura) leads to enhanced aggregation of platelets on ultralarge-
VWF multimers and consequently to microangiopathic haemolytic
anaemia and thrombocytopenia.
Use of left ventricular assist devices (LVADs) for treating end-stage
heart failure is becoming more and more important for patients
awaiting heart transplantation [9]. Furthermore, LVADs are also increas-
ingly implanted in patients as destination therapy, when heart trans-
plantation is not considered as an option [10]. Artiﬁcial surfaces andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of the ﬁbrinolytic system [11]. As thromboembolic events are frequent
with these devices, the patients require adequate anticoagulation [12,
13]. A combination of platelet inhibitors and a vitamin K antagonist is
often used in these patients [14]. Also, bleeding complications, mainly
gastrointestinal bleeding, have been reported in left ventricular assist
device recipients [15], which cannot be solely explained by the
anticoagulation therapy. Furthermore,markedly impaired platelet func-
tion was observed in outpatients with left ventricular assist devices [8]:
platelet function under high shear rates was severely compromised,
ristocetin-induced platelet aggregation was also reduced. Although
von Willebrand factor antigen levels (VWF:Ag) were 80% higher than
in healthy individuals, subnormal VWF activity, measured as
ristocetin-cofactor activity (VWF:RCO) levels were found in some pa-
tients. Western blot analysis of VWF multimers revealed an abnormal
VWF multimeric pattern: degradation of high molecular weight
multimers (HMWM) was accompanied by enhanced triplet structure
and increased low molecular weight multimers (LMWM). This picture
resembles type 2A von Willebrand disease. Acquired von Willebrand
disease was also conﬁrmed in patients with two different types of
LVAD [16], and a lower VWF:RCO/VWF:Ag ratio was associated with
larger transfusion requirements.
We hypothesised that an ex vivo model could be established to
study whether mechanical shear alone causes an acquired VWD 2A or
whether this process also depends on the VWF cleavage protein
ADAMTS-13. Therefore we used blood from healthy volunteers and
two stable patients with congenital thrombotic thrombocytopenic pur-
pura (TTP). Further, we wanted to knowwhether platelets are essential
for the cleavage of the large multimers during LVAD circulation. Thus,
we compared the effect of circulating platelet rich plasma (PRP) to cir-
culating platelet poor plasma on the multimeric pattern of VWF.
2. Material and methods
2.1. Study design and subject population
The Ethics Committee of the Medical University of Vienna approved
the study protocol, and the studywas conducted in accordancewith the
Declaration of Helsinki.Written informed consentwas obtained fromall
healthy volunteers and patients before the study entry.
Twelve healthy male and female volunteers (m/f ratio 6/6; age 23
years, range: 18–59, body mass index 24 ± 34.2 kg/m2; mean ± stan-
dard deviations) and two patients with congenital ADAMTS-13 deﬁ-
ciency were included in this study, one of whom is on biweekly
treatment with plasma infusion. Healthy subjects were excluded if
they had abnormal ﬁndings in medical history and physical examina-
tion unless the investigator considered this abnormality clinically irrel-
evant. Seropositivity for hepatitits B virus surface antigen, hepatitis C
virus or human immunodeﬁciency virus-1/2 antibodies, blood donation
during one month prior to the study, pregnancy and use of medication
during two weeks before the start of the study (which the investigator
considers may affect the validity of the study) precluded a subject
from being enrolled.
Healthy volunteers underwent a single whole blood donation of ap-
proximately 240 mL. Vital parameters were measured before and after
blood withdrawal. The two female congenital TTP patients, who were
described inmore detail previously in another trial [17], also underwent
blood donation (240 mL). Blood was sampled in citrate dextrose (1:9)
containing bags.
2.2. Ex vivo experiments
A hydraulic circuit was established using a medically approved left
ventricular assist device (Heartware HVAD®, Heartware Inc., Miami
Lakes, FL) connected to a ﬂuid reservoir by medical grade silicone tub-
ings (Degania Silicone Ltd., Israel) and a medical gradepolyvinylchloride (PVC) tubing (Tygon® S50 HL, Saint-Gobain Perfor-
mance Plastics, Akron, OH) (see Supplementary Fig. 2 for setup of cir-
cuit). The reservoir was a custom made thin-walled silicone tubing
(wall thickness 0.6 mm) out of casting silicone (Köraform A42,
Kömmerling Chemische Fabrik GmbH, Germany). This allowed oxygen-
ation of the blood by ambient atmosphere during the test. Paired tests
with two circuits were performed at 37 °C in an incubator (Duomax
1030T/Inkubator 1000, Heidolph Instruments GmbH & Co.KG,
Germany). The priming volume of the setup with 90 mL allowed the
use the blood of one donation in both circuits. Apart from the pumps,
all blood contacting parts were exchanged for each experiment. The
pumps were cleaned immediately after the tests by running for 1 h in
alkaline cleaning ﬂuid (S + M® Labor, Schülke & Mayr GmbH, Vienna,
Austria), for 24 h in instrument disinfectant (Sekusept® plus, Ecolab
Deutschland GmbH, Düsseldorf, Germany) and for 24 h in deionized
water. Pump speed was set to 1800 rpm and circulating blood volume
to 5 L/min by adjusting the ﬂow resistance, to correspond to approxi-
mately the in vivo use in humans. We had also applied higher pump
speeds (up to 3000 rpm) in ﬁrst experiments, but the circulating
blood was too haemolytic for further analysis. Pressure was measured
at the pump inlet and the pump outlet by a disposable pressure trans-
ducer (TruWave Pressure Transducer, Edwards Lifesciences Corp., Ir-
vine, CA). Citrate phosphate dextrose solution (1:7) or heparin (5 U/
mL) anticoagulated blood circulated for 2 h in the extracorporeal circuit.
As shown in a recent study [18], we could not detect any difference be-
tween the two anticoagulants in terms of any tested parameter (VWF
multimers and assays). Two circuits were run in parallel for whole
blood experiments and the blood from patients with congenital TTP;
the reduction inmultimer bandswas comparable between both circuits
and the difference in the number of multimer bands was 0–1 bands in
all cases. A mean was taken for statistical comparisons.2.3. Laboratory analysis
VWF:Ag was measured with a fully automated simultaneous ther-
mal analyser using the STA Liatest VWF (Diagnostica Stago, Paris,
France). VWF:RCo was assayed by turbidometry using a commercial
kit (BC vonWillebrand reagent; DadeBehring, Marburg, Germany) [19].
Determination of VWF multimers was performed on sodium dode-
cyl sulphate-agarose discontinuous electrophoresis (1.2% agarose gel)
using LGT agarose type VII (Sigma, Munich, Germany). The VWF
multimers were transferred to nitrocellulose ﬁlters by electroblotting.
Filterswere incubated at room temperature in a 1:3000 dilution of poly-
clonal rabbit anti-human VWF–horseradish peroxidase antibody (Dako,
Glostrup, Denmark). After several washing steps, SuperSignalWest Pico
Chemiluminescent Substrate (Pierce, Rockford, IL) was added to the ﬁl-
ters. Detection of multimers was performed by using the luminescent
image analyser LAS 3000 (Fujiﬁlm Life Science, Duesseldorf, Germany).
The ADAMTS-13 activity was determined by a commercially avail-
able assay (Technozym ADAMTS-13 activity ELISA; lower limit of quan-
tiﬁcation: 0.35%). Plasma samples were diluted 1:1 and 1:2 prior to
analysis as duplicates. ADAMTS-13 antigen levels were determined by
a commercially available assay (Technozym ADAMTS-13 Antigen
ELISA); plasma samples of healthy volunteers were diluted 1:5 prior
to analysis.
Platelet function was measured in healthy volunteers by the
Multiplate analyser (MEA; Multiplate; Dynabyte Medical, Munich,
Germany), as previously described [20]. Blood was drawn into tubes
containing hirudin as an anticoagulant and diluted with saline solution
(0.9%) at a 1:1 ratio and incubated for three minutes. After stirring at
37 °C, platelet agonists, ADP (6.5 μM), arachidonic acid (0.5 mM),
ristocetin (0.77 mg/mL) and TRAP-6 (32 μM)were added and aggrega-
tion was continuously recorded for 5 min. Aggregation was quantiﬁed
as area under the curve (AUC), an integrated measure of velocity and
maximal aggregation, and expressed as units (U).
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Data are described as mean ± SD or median and the range. Data
were log transformed before comparison with t-tests. A p-value ≤0.05
was considered signiﬁcant. After initial experiments we estimated to
observe an average reduction of 3 multimer bands against a SD of 1
multimer band.We calculated that 3 subjectswould sufﬁce for that pur-
pose (β=0.9, α=0.05). Additional subjects were recruited for exper-
iments with whole blood to allow a better estimate of the inter-subject
variability.
3. Results
3.1. LVAD circulation decreases HMWMonly in the presence of ADAMTS-13
In initial experiments we examined the time-lag before themaximal
effect on multimers became apparent. Blood circulation at high shear
rates decreased HMWM within 15 min. The maximal effect was ob-
served at 1–2 h with no further decrease at 4 h (data shown in Supple-
mentary Fig. 1). Therefore all further experimentswere carried out after
2 h circulation time.
In vitro circulation of whole blood signiﬁcantly decreasedHMWMof
normal volunteers. Up to 14–15multimer bandswere visible on the gels
at baseline, whichwere reduced by an average of 3 up to amaximum of
6–7multimer bands, corresponding to an average 59% lower densitom-
etry signal of HMWM (p b 0.01). For that purpose we only analysed the
densitometry of the higher multimer region, i.e. the upper 25% of the
gel. It was accompanied by enhanced triplet structure and increased
density of lowmolecularweightmultimers (Fig. 1; this plot is represen-
tative for the experiments in healthy individuals). In contrast, extracor-
poreal circulation reduced HMWM by only 0–1 multimer bands in the
two patients with congenital TTP patients (p b 0.005 vs. healthy con-
trols). The patient with the slight reduction had normal platelet counts,
whereas the other patient, who had no reduction in multimers, wasFig. 1. Reduction of highmolecular weight multimers by extracorporeal circulation in left ventr
plasma from one healthy volunteer before extracorporeal circulation. Lanes 4, 7: plasma fromthrombocytopenic (82 × 109/L) and received her biweekly plasma infu-
sion immediately after the blood donation. At baseline, these patients
had only a slightly increased HMWH number than normal controls,
whichmay be a result of the gel strengthwhichwas optimized to detect
a depletion of multimers rather than detecting the ultra-large
multimers.
3.2. Platelets are essential for HMWH consumption
When platelet rich plasma of healthy volunteers circulated for 2 h,
the decrease of the large multimers was similar to that in whole blood
(Fig. 2, left bottom layer). In contrast, HMWmultimers decreased only
by a minor degree after circulation of platelet poor plasma (p b 0.001
vs whole blood; Fig. 2, right bottom layer).
3.3. Associated decrease in VWF:RCO/VWF:Ag ratio and ADAMTS-13 levels
The extracorporeal circulation rapidly decreased VWF:RCO levels
92 ± 19% to 40 ± 14% (p b 0.001) in vitro, whereas baseline vWF:Ag
levels (91 ± 29%) were not altered (p N 0.05). Thus, the VWF:RCO/
VWF:Ag ratio decreased from 0.94 ± 29 to values below the normal
range (0.51 ± 11; p b 0.001; Fig. 2). The ADAMTS-13 activity levels
dropped signiﬁcantly from 108±20% to 52±21% after the extracorpo-
real circulation of normal blood (p b 0.001), but therewas no signiﬁcant
difference in ADAMTS-13 antigen levels between samples obtained be-
fore (1.5 ± 0.2 μg/mL) and after the circulation (1.4 ± 0.2 μg/mL).
3.4. Platelet function
Extracorporeal circulation impaired platelet function of healthy vol-
unteers as measured by the multiple electrode aggregometry. Aggrega-
tion tests in response to four different agonists signiﬁcantly and
markedly decreased after the extracorporeal circulation (p b 0.005).icular assist device. Lanes 1, 2, 5, 9, 10: commercial and in house plasma pools. Lanes 3, 6:
the same healthy volunteer after 2 h of extracorporeal circulation.
Fig. 2. Reduction inmultimer bands after 2 h of extracorporeal circulation in left ventricular assist device circuit. A) normalwhole blood; B)ADAMTS-13 deﬁcient patientswith thrombotic
thrombocytopenic purpura, C) normal platelet rich plasma; D) normal platelet poor plasma. **p ≤ 0.005 A vs. B and A vs. D. Box plots showmean ± SD and ranges; individual values are
depicted by open circles and ordered by magnitude of effect size. Multimer patterns depict representative experiments: lane 1 before, lane 2 after the extracorporeal circulation, lane 3
control plasma.
Table 1
Platelet aggregation in whole blood before and after extracorporeal circulation.
Before extracorp. circulation After extracorp. circulation
ADP (U) 77 (51–89) 19 (0–76)**
Arachidonic acid (U) 80 (23–100) 46 (0–102)**
Ristocetin (U) 116 (64–135) 51 (0–97)**
TRAP (U) 96 (77–107) 37 (0–73)**
Medians and the range; **p b 0.005; (n = 12).
ADP = adenosine diphosphate.
TRAP = thrombin receptor activating peptide.
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The aim of this study was to further investigate the mechanism of
VWF depletion by use of an ex vivo LVADmodel, to help delineate ifme-
chanical shear alone causes an acquired VWD or if this process also de-
pends on theVWF cleavage protein ADAMTS-13.We adjusted the pump
speed (1800 rpm) and circulating blood volume (5 L/min) of the LVAD
device to correspond to in vivo use in humans, in order to determine the
effect of LVADon themultimeric pattern of VWF, on VWF:RCO levels, on
ADAMTS-13 levels and on platelet function under controlled conditions.
As shown in a recent study [18]we observed a decrease of large VWF
multimers after the exposure ofwhole blood to LVAD in vitro. This dem-
onstrates that LVAD rapidly causes acquired VWD 2A, which is charac-
terized by the loss of large VWF multimers. This was nicely reﬂected
by a decrease of the VWF:RCO/VWF:Ag ratio and of ADAMTS-13 levels
after the extracorporeal circulation. A VWF:RCO/VWF:Ag ratio below
0.7 suggests an impaired function of VWF. The drop of ADAMTS-13 indi-
cates its consumption by cleaving the VWF, but antigen levels remain
unchanged in this closed circulation. The ADAMTS-13 consumption is
in agreement with the high ADAMTS-13 turnover in experimental
models of VWF release (desmopressin as well as human endotoxemia
[21,22]) but also in various diseases [23]. In contrast congenital
ADAMTS-13 deﬁciency prevented from a loss of large multimers by
LVAD. Therefore, ADAMTS-13 appears essential for the decrease of the
HMWM of VWF in patients with LVAD. Our ﬁndings are at variance to
a study by Bartoli et al. [24], who postulated that the major mechanism
of VWF degradation is mainly due to mechanical destruction of VWF,
with ADAMTS-13 playing a smaller role. In that study, LVADS were im-
planted in calves. Similar to humans [25,26], the VWF:RCo/VWF:Ag
ratio decreased and the HMWMwere absent after seven days of LVAD
support, but ADAMTS-13 protein and activity increased. As in our closed
system no in vivo production of ADAMTS-13 is possible, we are able to
demonstrate that ADAMTS-13 plays a major role in the proteolytic
cleavage of VWF during the LVAD treatment.Next, we examined the role of platelets in the development of ac-
quired VWD 2A caused by LVAD. Similar to whole blood, large
multimers decreased after circulation of normal platelet rich plasma of
healthy volunteers. In contrast, only a slight decline of HMWM could
be detected (Fig. 2), when platelet poor plasma circulated for 2 h.
These ﬁndings suggest that platelets may also play an important role
in the cleavage of VWF. In a model using a vortexer and puriﬁed VWF
for 4 h, shear stress alone caused physical demolition of larger into
smaller VWF multimers, and ADAMTS-13 cleaved large multimers into
degradation fragments [27]. Our results do not contradict those ﬁndings
but point towards an additional involvement of platelets in our in vitro
LVAD model which mimics the shear rates of LVAD devices implanted
in vivo. Differences in the models or the duration of circulation may ac-
count for the contribution of platelets in our circuit. VWF may self-
assemble on platelets [28], and VWF binding to the GPIb complex of
platelets may facilitate the stretching and subsequently the cleavage
of VWF. However, further studies are necessary to deﬁne the exact
role of platelets in the cleavage process. In addition, our data show
that LVAD rapidly and markedly reduced platelet aggregation in re-
sponse to various agonists, which may contribute to diminished
haemostasis and bleeding complications in LVAD patients. Responses
to arachidonic acid, ADP and TRAP-6 were all markedly decreased
(Table 1) and reﬂect a decrease in platelet function. In contrast, the
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creasing VWF activity. These ﬁndings are in good agreement with and
extend previous data in outpatients with left ventricular assist devices
[8]. Steinlechner et al. observed abnormal ristocetin induced platelet ag-
gregation, a decrease of the VWF:RCo/vWF:Ag ratio and an almost de-
pletion of the HMWM. The severely impaired VWF-dependent platelet
aggregation tests could also be conﬁrmed in sixteen patients with a
continuous-ﬂow LVAD [29]. In another study the rate of bleeding com-
plications was compared in patients with continuous-ﬂow devices to
patients with pulsatile ﬂow devices [30]. Patients with continuous
ﬂowdevices had a higher incidence of bleeding events and required sig-
niﬁcantly higher amounts of blood products. All these patients had de-
creased to absent large VWF multimers. Although all continuous ﬂow
LVAD recipients had acquired VWD, not all recipients experienced
bleeding complications [31]. Therefore HMWM deﬁciency cannot ex-
plain alone why some patients bleed and others do not suffer from
bleeding complications.
Limitations of thismodel include that only a limited amount of blood
or plasma circulates up to 50 times per minute in the circuit. Therefore,
the timedependent evolution of VWFmultimer depletionmay be accel-
erated in vitro as compared to in humans. However, the amount of
blood needed in each experiment (250mL) is too high for additional ex-
periments with antibodies or recombinant ADAMTS-13 because of cost
reasons. The in vitro system is devoid of ongoing in vivo production of
ADAMTS-13, VWF and platelets, and their changes during acute phase
reactions. The minimal rotor speed is 1800 rpm and therefore does
not allow tomeasure the inﬂuence of lower shear rates on VWF. Platelet
function may be also different in vivo because of concomitant medica-
tion. Finally, the number of patients with congenital ADAMTS-13 deﬁ-
ciency was small. However, this disease is extremely rare, and the
number was sufﬁcient to demonstrate a signiﬁcant effect. Finally the
challenge with in vitro models is fully capturing the biology of events
that occur in vivo. Various miniature models have been used previously
including capillaries to demonstrate shear stress dependent proteolytic
cleavage of VWFbyADAMTS-13 [32] or force probemolecular dynamics
simulations to demonstrate shear dependent elongation and unfolding
of VWF [33]. In contrast to these micro-models our macro-model actu-
ally uses LVAD pumps that are implanted in patients with terminal
heart failure. These patients have altered glycosylation of proteins [34,
35], and glycosylation of VWF affects ADAMTS-13 dependent VWF
cleavage [36,37]. Thus we cannot entirely exclude that blood from
heart failure patientsmay react differently. Unfortunatelywe are unable
to address that experimentally, because ourmacro-model needs 250mL
of blood, and such large blood draws should be avoided in typically
anaemic heart failure patients for ethical reasons.
In summary, our in vitro model of LVAD induced acquired VWD
demonstrated that ADAMTS-13 activity and platelets are essential for
the depletion of HMWM of VWF. Furthermore, this combined model
of contact activation of coagulation on artiﬁcial surfaces and high
shear rates could also be used to test antiplatelet drugs or
anticoagulants.
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